Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received Hainan supervision from the China Securities Regulatory Commission...
Zhitong Finance App News, Puli Pharmaceuticals (300630.SZ) issued an announcement. The company recently received the “Decision on Ordering Corrective Measures against Hainan Puli Pharmaceutical Co., Ltd.” (Decision on Administrative Supervision Measures (2024) No. 14) issued by the Hainan Regulatory Bureau of the China Securities Regulatory Commission.
According to reports, during an on-site inspection, the Hainan Securities Regulatory Bureau discovered that financial information such as operating income and profit was not accurately disclosed in the company's 2021 and 2022 annual reports. The above acts of the company violate the provisions of Article 3 (1) of the “Administrative Measures on Information Disclosure of Listed Companies” (Securities Regulatory Commission Order No. 182).
According to the provisions of Article 52 (1) of the “Administrative Measures on Information Disclosure of Listed Companies”, the Hainan Securities Regulatory Bureau decided to take corrective administrative supervision measures against the company and record the relevant irregularities in the capital market integrity file database.